Development and implementation of an interdisciplinary telemedicine clinic for older patients with cancer-Preliminary data.
asynchronous assessment
geriatric assessment
geriatric oncology
hybrid model
telemedicine
Journal
Journal of the American Geriatrics Society
ISSN: 1532-5415
Titre abrégé: J Am Geriatr Soc
Pays: United States
ID NLM: 7503062
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
03
01
2023
received:
14
11
2022
accepted:
17
01
2023
pmc-release:
01
05
2024
medline:
12
5
2023
pubmed:
7
2
2023
entrez:
6
2
2023
Statut:
ppublish
Résumé
Frailty assessment is an important marker of the older adult's fitness for cancer treatment independent of age. Pretreatment geriatric assessment (GA) is associated with improved mortality and morbidity outcomes but must occur in a time sensitive manner to be useful for cancer treatment decision making. Unfortunately, time, resources and other constraints make GA difficult to perform in busy oncology clinics. We developed the Cancer and Aging Interdisciplinary Team (CAIT) clinic model to provide timely GA and treatment recommendations independent of patient's physical location. The interdisciplinary CAIT clinic model was developed utilizing the surge in telemedicine during the COVID-19 pandemic. The core team consists of the patient's oncologist, geriatrician, registered nurse, pharmacist, and registered dietitian. The clinic's format is flexible, and the various assessments can be asynchronous. Patients choose the service method-in person, remotely, or hybrid. Based on GA outcomes, the geriatrician provides recommendations and arrange interventions. An assessment summary including life expectancy estimates and chemotoxicity risk calculator scores is conveyed to and discussed with the treating oncologist. Physician and patient satisfaction were assessed. Between May 2021 and June 2022, 50 patients from multiple physical locations were evaluated in the CAIT clinic. Sixty-eight percent was 80 years of age or older (range 67-99). All the evaluations were hybrid. The median days between receiving a referral and having the appointment was 8. GA detected multiple unidentified impairments. About half of the patients (52%) went on to receive chemotherapy (24% standard dose, 28% with dose modifications). The rest received radiation (20%), immune (12%) or hormonal (4%) therapies, 2% underwent surgery, 2% chose alternative medicine, 8% were placed under observation, and 6% enrolled in hospice care. Feedback was extremely positive. The successful development of the CAIT clinic model provides strong support for the potential dissemination across services and institutions.
Sections du résumé
BACKGROUND
Frailty assessment is an important marker of the older adult's fitness for cancer treatment independent of age. Pretreatment geriatric assessment (GA) is associated with improved mortality and morbidity outcomes but must occur in a time sensitive manner to be useful for cancer treatment decision making. Unfortunately, time, resources and other constraints make GA difficult to perform in busy oncology clinics. We developed the Cancer and Aging Interdisciplinary Team (CAIT) clinic model to provide timely GA and treatment recommendations independent of patient's physical location.
METHODS
The interdisciplinary CAIT clinic model was developed utilizing the surge in telemedicine during the COVID-19 pandemic. The core team consists of the patient's oncologist, geriatrician, registered nurse, pharmacist, and registered dietitian. The clinic's format is flexible, and the various assessments can be asynchronous. Patients choose the service method-in person, remotely, or hybrid. Based on GA outcomes, the geriatrician provides recommendations and arrange interventions. An assessment summary including life expectancy estimates and chemotoxicity risk calculator scores is conveyed to and discussed with the treating oncologist. Physician and patient satisfaction were assessed.
RESULTS
Between May 2021 and June 2022, 50 patients from multiple physical locations were evaluated in the CAIT clinic. Sixty-eight percent was 80 years of age or older (range 67-99). All the evaluations were hybrid. The median days between receiving a referral and having the appointment was 8. GA detected multiple unidentified impairments. About half of the patients (52%) went on to receive chemotherapy (24% standard dose, 28% with dose modifications). The rest received radiation (20%), immune (12%) or hormonal (4%) therapies, 2% underwent surgery, 2% chose alternative medicine, 8% were placed under observation, and 6% enrolled in hospice care. Feedback was extremely positive.
CONCLUSIONS
The successful development of the CAIT clinic model provides strong support for the potential dissemination across services and institutions.
Identifiants
pubmed: 36744590
doi: 10.1111/jgs.18267
pmc: PMC10175129
mid: NIHMS1869425
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1638-1649Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2023 The American Geriatrics Society.
Références
Geriatrics (Basel). 2019 Jun 24;4(2):
pubmed: 31238518
BMC Geriatr. 2020 Jul 6;20(1):231
pubmed: 32631254
Bull World Health Organ. 2017 May 1;95(5):368-374
pubmed: 28479638
J Am Geriatr Soc. 2006 Apr;54(4):720-2
pubmed: 16686895
J Am Geriatr Soc. 2003 Oct;51(10):1451-4
pubmed: 14511167
J Aging Phys Act. 2019 Apr 1;27(2):230-233
pubmed: 30117359
Curr Oncol Rep. 2017 Oct 2;19(11):75
pubmed: 28971292
J Natl Compr Canc Netw. 2016 Nov;14(11):1357-1370
pubmed: 27799507
J Clin Oncol. 2016 Jul 10;34(20):2366-71
pubmed: 27185838
N Engl J Med. 2002 Apr 4;346(14):1061-6
pubmed: 11932474
Lancet Healthy Longev. 2022 Sep;3(9):e617-e627
pubmed: 36102776
Alzheimer Dis Assoc Disord. 2013 Jan-Mar;27(1):37-43
pubmed: 22193353
Front Surg. 2021 Aug 12;8:690680
pubmed: 34458314
Curr Probl Cancer. 2021 Jun;45(3):100699
pubmed: 33468334
J Oncol Pract. 2017 Feb;13(2):107-112
pubmed: 28972835
JAMA. 1963 Sep 21;185:914-9
pubmed: 14044222
Br J Cancer. 2015 Apr 28;112(9):1435-44
pubmed: 25871332
Crit Rev Oncol Hematol. 2005 Sep;55(3):241-52
pubmed: 16084735
Oncologist. 2014 Oct;19(10):1056-68
pubmed: 25187477
BMJ Qual Saf. 2014 Apr;23(4):290-8
pubmed: 24025320
J Clin Oncol. 2021 Feb 20;39(6):608-618
pubmed: 33444080
JAMA Netw Open. 2020 Aug 3;3(8):e209265
pubmed: 32822490
JAMA Oncol. 2021 Nov 01;7(11):e214158
pubmed: 34591080
Res Q Exerc Sport. 1999 Jun;70(2):113-9
pubmed: 10380242
Curr Hematol Malig Rep. 2022 Feb;17(1):31-38
pubmed: 35028826
Am J Nurs. 2008 Apr;108(4):52-62; quiz 62-3
pubmed: 18367931
J Am Geriatr Soc. 2019 Apr;67(4):674-694
pubmed: 30693946
Nestle Nutr Workshop Ser Clin Perform Programme. 1999;1:3-11; discussion 11-2
pubmed: 11490593
JCO Oncol Pract. 2021 Jun;17(6):336-344
pubmed: 33064058
J Gen Intern Med. 2009 Oct;24(10):1115-22
pubmed: 19649678
J Natl Compr Canc Netw. 2017 Feb;15(2):172-179
pubmed: 28188187
JAMA Oncol. 2020 Feb 1;6(2):196-204
pubmed: 31697365
Crit Rev Oncol Hematol. 2011 Sep;79(3):302-7
pubmed: 20888781
J Clin Oncol. 2020 Aug 1;38(22):2558-2569
pubmed: 32250717
J Clin Oncol. 2018 Aug 1;36(22):2326-2347
pubmed: 29782209
Haematologica. 2022 May 01;107(5):1172-1180
pubmed: 34551505
Int J Nurs Stud Adv. 2020 Nov;2:100008
pubmed: 33083791
J Clin Oncol. 2021 Jul 1;39(19):2195-2204
pubmed: 34043453
Lancet. 2021 Nov 20;398(10314):1894-1904
pubmed: 34741815